Search

1 to 10 of 295
Sort by

Library Entry
Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors

HuMax-IL8 (now known as BMS-986253) is a novel, fully human monoclonal antibody that inhibits interleukin-8 (IL-8), a chemokine that promotes tumor progression, immune escape, epithelial-mesenchymal transition, and recruitment of myeloid-derived suppressor cells. Studies have demonstrated that...


Library Entry
Influence of low-dose radiation on abscopal responses in patients receiving high-dose radiation and immunotherapy

Preclinical evidence suggests that low-dose radiation may overcome the inhibitory effects of the tumor stroma and improve a tumor’s response to immunotherapy, when combined with high-dose radiation to another tumor. The aim of this study was to evaluate tumor responses to this combination in a...


Library Entry
2018 Advances in Cancer Immunotherapy™ Post Program Webinar Series - Atlanta Webinar 1

From the Society for Immunotherapy of Cancer (SITC) for clinical oncologists, registered nurses, pharmacists, emergency physicians and the entire cancer care team, the Advances in Cancer Immunotherapy™ (ACI) post-program webinar recording for the Atlanta event is provided here. The purpose of...

Advances in Cancer Immunotherapy™ Post-Program Webinar 1 (Atlanta).mp4


Library Entry
2017 Advances in Cancer Immunotherapy™ Post Program Webinar Series - Washington, DC Webinar 1

From the Society for Immunotherapy of Cancer (SITC) for clinical oncologists, registered nurses, pharmacists, emergency physicians and the entire cancer care team, the Advances in Cancer Immunotherapy™ (ACI) post-program webinar recording for the Washington, DC event is provided here. The...

Advances in Cancer Immunotherapy™ Post-Program Webinar 1 (Washington, D.C.).mp4


Library Entry
2017 Advances in Cancer Immunotherapy™ Post Program Webinar Series - Pittsburgh Webinar 1

From the Society for Immunotherapy of Cancer (SITC) for clinical oncologists, registered nurses, pharmacists, emergency physicians and the entire cancer care team, the Advances in Cancer Immunotherapy™ (ACI) post-program webinar recording for the Pittsburgh event is provided here. The purpose of...

Advances in Cancer Immunotherapy™ Post-Program Webinar 1 (Pittsburgh).mp4


Library Entry
2017 Advances in Cancer Immunotherapy™ Post Program Webinar Series - Philadelphia Webinar 2

From the Society for Immunotherapy of Cancer (SITC) for clinical oncologists, registered nurses, pharmacists, emergency physicians and the entire cancer care team, the Advances in Cancer Immunotherapy™ (ACI) post-program webinar recording for the Philadelphia event is provided here. The purpose...

Advances in Cancer Immunotherapy™ Post-program Webinar 2 (Philadelphia).mp4


Library Entry
2017 Advances in Cancer Immunotherapy™ Post Program Webinar Series - Los Angeles Webinar 1

From the Society for Immunotherapy of Cancer (SITC) for clinical oncologists, registered nurses, pharmacists, emergency physicians and the entire cancer care team, the Advances in Cancer Immunotherapy™ (ACI) post-program webinar recording for the Los Angeles event is provided here. The purpose...

Advances in Cancer Immunotherapy™ I-O Cup O' Joe Webinar 1 (Los Angeles).mp4


Library Entry
2017 Advances in Cancer Immunotherapy™ Post Program Webinar Series - Houston Webinar 2

From the Society for Immunotherapy of Cancer (SITC) for clinical oncologists, registered nurses, pharmacists, emergency physicians and the entire cancer care team, the Advances in Cancer Immunotherapy™ (ACI) post-program webinar recording for the Houston event is provided here. The purpose of...

Advances in Cancer Immunotherapy™ Post-Program Webinar 2 (Houston).mp4



Library Entry
Phase I study of samalizumab in chronic lymphocytic leukemia and multiple myeloma: blockade of the immune checkpoint CD200

Samalizumab is a novel recombinant humanized monoclonal antibody that targets CD200, an immunoregulatory cell surface member of the immunoglobulin superfamily that dampens excessive immune responses and maintains self-tolerance. This first-in-human study investigated the therapeutic use of...